FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ASAH1-ANKZF1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ASAH1-ANKZF1
FusionPDB ID: 6930
FusionGDB2.0 ID: 6930
HgeneTgene
Gene symbol

ASAH1

ANKZF1

Gene ID

427

55139

Gene nameN-acylsphingosine amidohydrolase 1ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1
SynonymsAC|ACDase|ASAH|PHP|PHP32|SMAPMEVms1|ZNF744
Cytomap

8p22

2q35

Type of geneprotein-codingprotein-coding
Descriptionacid ceramidaseN-acylethanolamine hydrolase ASAH1N-acylsphingosine amidohydrolase (acid ceramidase) 1acid CDaseacylsphingosine deacylaseputative 32 kDa heart proteinankyrin repeat and zinc finger domain-containing protein 1ankyrin repeat and zinc finger domain containing 1zinc finger protein 744
Modification date2020031320200313
UniProtAcc

Q13510

Main function of 5'-partner protein: FUNCTION: Lysosomal ceramidase that hydrolyzes sphingolipid ceramides into sphingosine and free fatty acids at acidic pH (PubMed:10610716, PubMed:7744740, PubMed:15655246, PubMed:11451951). Ceramides, sphingosine, and its phosphorylated form sphingosine-1-phosphate are bioactive lipids that mediate cellular signaling pathways regulating several biological processes including cell proliferation, apoptosis and differentiation (PubMed:10610716). Has a higher catalytic efficiency towards C12-ceramides versus other ceramides (PubMed:7744740, PubMed:15655246). Also catalyzes the reverse reaction allowing the synthesis of ceramides from fatty acids and sphingosine (PubMed:12764132, PubMed:12815059). For the reverse synthetic reaction, the natural sphingosine D-erythro isomer is more efficiently utilized as a substrate compared to D-erythro-dihydrosphingosine and D-erythro-phytosphingosine, while the fatty acids with chain lengths of 12 or 14 carbons are the most efficiently used (PubMed:12764132). Has also an N-acylethanolamine hydrolase activity (PubMed:15655246). By regulating the levels of ceramides, sphingosine and sphingosine-1-phosphate in the epidermis, mediates the calcium-induced differentiation of epidermal keratinocytes (PubMed:17713573). Also indirectly regulates tumor necrosis factor/TNF-induced apoptosis (By similarity). By regulating the intracellular balance between ceramides and sphingosine, in adrenocortical cells, probably also acts as a regulator of steroidogenesis (PubMed:22261821). {ECO:0000250|UniProtKB:Q9WV54, ECO:0000269|PubMed:10610716, ECO:0000269|PubMed:11451951, ECO:0000269|PubMed:12764132, ECO:0000269|PubMed:12815059, ECO:0000269|PubMed:15655246, ECO:0000269|PubMed:17713573, ECO:0000269|PubMed:22261821, ECO:0000269|PubMed:7744740, ECO:0000303|PubMed:10610716}.; FUNCTION: [Isoform 2]: May directly regulate steroidogenesis by binding the nuclear receptor NR5A1 and negatively regulating its transcriptional activity. {ECO:0000305|PubMed:22927646}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000262097, ENST00000314146, 
ENST00000381733, ENST00000417108, 
ENST00000520051, ENST00000520781, 
ENST00000323348, ENST00000409849, 
ENST00000410034, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 16 X 7=16804 X 4 X 3=48
# samples 164
** MAII scorelog2(16/1680*10)=-3.39231742277876
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/48*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ASAH1 [Title/Abstract] AND ANKZF1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ASAH1 [Title/Abstract] AND ANKZF1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ASAH1(17921965)-ANKZF1(220099547), # samples:1
Anticipated loss of major functional domain due to fusion event.ASAH1-ANKZF1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ASAH1-ANKZF1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ASAH1-ANKZF1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ASAH1-ANKZF1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneASAH1

GO:0046512

sphingosine biosynthetic process

12815059

HgeneASAH1

GO:0046513

ceramide biosynthetic process

12764132|12815059

HgeneASAH1

GO:0046514

ceramide catabolic process

12815059



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:17921965/chr2:220099547)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ASAH1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ANKZF1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000262097ASAH1chr817921965-ENST00000323348ANKZF1chr2220099547+1970769151745576
ENST00000262097ASAH1chr817921965-ENST00000409849ANKZF1chr2220099547+1970769151745576
ENST00000262097ASAH1chr817921965-ENST00000410034ANKZF1chr2220099547+1950769151745576
ENST00000381733ASAH1chr817921965-ENST00000323348ANKZF1chr2220099547+187367251648547
ENST00000381733ASAH1chr817921965-ENST00000409849ANKZF1chr2220099547+187367251648547
ENST00000381733ASAH1chr817921965-ENST00000410034ANKZF1chr2220099547+185367251648547
ENST00000314146ASAH1chr817921965-ENST00000323348ANKZF1chr2220099547+1824623221599525
ENST00000314146ASAH1chr817921965-ENST00000409849ANKZF1chr2220099547+1824623221599525
ENST00000314146ASAH1chr817921965-ENST00000410034ANKZF1chr2220099547+1804623221599525

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000262097ENST00000323348ASAH1chr817921965-ANKZF1chr2220099547+0.0107159420.989284
ENST00000262097ENST00000409849ASAH1chr817921965-ANKZF1chr2220099547+0.0107159420.989284
ENST00000262097ENST00000410034ASAH1chr817921965-ANKZF1chr2220099547+0.0115714110.98842865
ENST00000381733ENST00000323348ASAH1chr817921965-ANKZF1chr2220099547+0.0345531630.9654468
ENST00000381733ENST00000409849ASAH1chr817921965-ANKZF1chr2220099547+0.0345531630.9654468
ENST00000381733ENST00000410034ASAH1chr817921965-ANKZF1chr2220099547+0.0380564370.9619436
ENST00000314146ENST00000323348ASAH1chr817921965-ANKZF1chr2220099547+0.040326520.9596735
ENST00000314146ENST00000409849ASAH1chr817921965-ANKZF1chr2220099547+0.040326520.9596735
ENST00000314146ENST00000410034ASAH1chr817921965-ANKZF1chr2220099547+0.0444026960.95559734

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ASAH1-ANKZF1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ASAH1chr817921965ANKZF1chr2220099547623200FTICTSIVAEDKKGSGSEGEDGFQVE
ASAH1chr817921965ANKZF1chr2220099547672222FTICTSIVAEDKKGSGSEGEDGFQVE
ASAH1chr817921965ANKZF1chr2220099547769251FTICTSIVAEDKKGSGSEGEDGFQVE

Top

Potential FusionNeoAntigen Information of ASAH1-ANKZF1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of ASAH1-ANKZF1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ASAH1-ANKZF1_17921965_220099547.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0303TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0303CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0307TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0307CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0315TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0315CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0315ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0324TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0324CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0804TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0804CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0820CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0820TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0820ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0831CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0831TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-0831ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1103TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1103CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1104CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1104TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1106TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1106CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1107TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1107CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1118CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1125TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1125CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1134TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1134CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1135CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1135TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1136TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1136CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1138CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1138TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1141CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1141TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1141ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1142CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1142TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1143CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1143TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1144CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1144TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1146CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1146TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1147TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1147CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1148TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1148CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1150CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1150TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1150ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1153TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1153CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1156CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1156TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1156ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1157CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1157TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1158CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1158TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1159TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1159CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1159ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1160CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1160TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1163TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1163CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1173TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1173CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1176TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1176CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1177CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1177TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1178CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1178TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1179TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1179CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1183TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1183CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1183ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1184CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1184TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1184ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1185TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1185CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1188CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1188TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1188ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1192TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1192CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1193CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1193TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1193ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1306CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1308TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1308CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1309TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1309CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1311CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1311TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1318TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1318CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1320TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1320CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1324TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1324CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1327TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1327CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1337TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1337CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1342CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1342TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1344TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1344CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1370TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1370CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1371TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1371CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1371ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1372TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1372CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1378TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1378CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1384TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1384CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1385TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1385CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1394TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1394CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1406TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1406CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1412TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1415TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1415CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1417TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1417CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1419TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1419CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1420TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1420CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1421TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1421CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1421ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1429TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1429CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1434TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1434CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1437TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1437CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1480TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1480CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1480ICTSIVAEDKKGSGS217
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1483TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1483CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1484TSIVAEDKKGSGSEG419
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1484CTSIVAEDKKGSGSE318
ASAH1-ANKZF1chr817921965chr2220099547769DRB1-1484ICTSIVAEDKKGSGS217

Top

Fusion breakpoint peptide structures of ASAH1-ANKZF1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ASAH1-ANKZF1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score

Top

Vaccine Design for the FusionNeoAntigens of ASAH1-ANKZF1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ASAH1-ANKZF1chr817921965chr2220099547217ICTSIVAEDKKGSGSTTTGTACTTCAATAGTAGCAGAAGACAAAAAAGGTTCAGGGTCGG
ASAH1-ANKZF1chr817921965chr2220099547318CTSIVAEDKKGSGSEGTACTTCAATAGTAGCAGAAGACAAAAAAGGTTCAGGGTCGGAGG
ASAH1-ANKZF1chr817921965chr2220099547419TSIVAEDKKGSGSEGCTTCAATAGTAGCAGAAGACAAAAAAGGTTCAGGGTCGGAGGGAG

Top

Information of the samples that have these potential fusion neoantigens of ASAH1-ANKZF1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample

Top

Potential target of CAR-T therapy development for ASAH1-ANKZF1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ASAH1-ANKZF1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ASAH1-ANKZF1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource